« Back
Home /
Roscovitine (Seliciclib)

Roscovitine (Seliciclib)

Item no.	M1974-25mg
Manufacturer	AbMole
CASRN	186692-46-6
Amount	25mg
Category	Oncology Food Safety Allergenes Hormones Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	0,9985
Citations	Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Rossi AG, et al . Nat Med. 2006 Sep,12(9):1056-64. PMID: 16951685 . Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. MacCallum DE, et al . Cancer Res. 2005 Jun 15,65(12):5399-407. PMID: 15958589 . Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Raje N, et al . Blood. 2005 Aug 1,106(3):1042-7. PMID: 15827128 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Seliciclib, CYC202
Similar products	Roscovitine, Seliciclib, CYC202
Available
Target Information	CDK
Molecular Weight	354, 45
Solubility	DMSO 60 mg/mL
Bioactivity information	Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1974-25mg-safety-datasheet.pdf